p53 Immunostaining and HPV DNA detection by PCR in cervical intraepithelial neoplasia: Clinical implications of a combinated evaluation

Anticancer Research

Volumn 17, Issue 1 B, 1997, Pages 555-560

  Garzetti, G Gioele ^a   Ciavattini, Andrea ^a   Lucarini, Guendalina ^a   Goteri, Gaia ^a   De Nictolis, Michele ^a   Fabris, Guidalberto ^a   Biagini, Graziella ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Cell proliferation; Cervical carcinoma; Cervical dysplasia; Cervical intraepithelial neoplasia; CIN; HPV infection; Immunohistochemistry; MIB 1; p53 immunostaining; Papillomavirus; PCR

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53; VIRUS DNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMA VIRUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; FEMALE; HUMANS; LONGITUDINAL STUDIES; METAPLASIA; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 0031050140     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lane DP, Benchimol S:p53 oncogene or anti-oncogene. Genes Devel 4: 1-8, 1990.
2. Rotter V, Prokocimer M: p53 and human malignancies. Adv Cancer Res 57: 257-272, 1991.
3. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991.
4. Stretch JR, Gatter KV, Raflkiaer E, Lane DP, Harris AL. Expression of mutant p53 in melanoma. Cancer Res 51: 5976-5979, 1991.
5. Porter PL, Gown AM, Kramp SG, Coltrera MD: Widespread p53 overexpression in human malignant tumors. Am J Pathol 140: 145-153, 1992.
6. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D: p53 expression in breast cancer. Int J Cancer 41: 178-183, 1988
7. Walker RA, Dearing SJ, Lane DP, Varley JM: Expression of p53 protein in infiltrating and in situ breast carcinomas. J Pathol 165: 203-11, 1991.
8. van der Berg FM, Tigges AJ, Schipper MET, den Hartog-Jager FCA, Kroes WGM, Walboomers JMM: Expression of the nuclear oncogene p53 in colon tumors. J Pathol 157; 193-159, 1989.
9. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP: p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87: 7555-7559, 1990.
10. Holm R, Skomedal H, Helland A, Kristensen G, Borresen AL, Nesland JM: Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol 169: 21-26, 1993.
11. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik I Midgley CA, Gannon JV, Lane DP: Aberrant expression of the p53 oncoprotein is common feature of a wide spectrum of malignancies. Oncogene 6: 1699-1703, 1991.
12. Gusterson BA, Anbazhagen R, Warren W, Midgely C, Lane DP, O'Hare M, Stamps A, Carter R, Jayatilake H: Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 6: 1785-175-89, 1991.
13. Bosari S, Roncalli M, Viale G, Bossi P, Coggi G: p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix. J Pathol 169: 425-430, 1993.
14. Oka K, Nakano T, Arai T: p53CM1 expression is not associated with prognosis in uterine cervical carcinoma. Cancer 72: 160-164, 1993.
15. Cardillo MR, Stamp GWH, Pignatelli MN, Lalani EN: Immunohistochemical analysis of p53 oncoprotein and proliferating cell nuclear antigen (PCNA) in the cervix uteri. Eur J Gynaec Oncol 14: 484-490, 1993.
16. Zhang WH, Coppleson M, Rose BR, Sorich EA, Nightingale BN, Thompson CH, Cossart YE, Bannatyne PM, Elliott PM, Atkinson KH: Papillomavirus and cervical cancer: a clinical and laboratory study. J Med Virol 26: 163-174, 1988.
17. Crook T, Wrede D, Vousden KH: p53 point mutation in HPV negative cervical carcinoma cell lines. Oncogene 6: 873-875, 1991.
18. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH: Clonal p53 mutation in primary cervical cancer: association with human papillomavirus-negattve tumours. Lancet 339: 1070-1073, 1992.
19. Garzetti GG, Ciavattini A, Goteri G, Menzo S, De Nictolis M, Clementi M, Brugia M, Romanini C: Vaginal micropapillary lesions are not related to human papillomuvirus infection: In situ hybridization and polymerase chain reaction detection techniques. Gynecol Obstet Invest 38: 134-139, 1994.
20. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beekmann AM, DeRouen TA, Galloway DA, Vernon D, Kiviat NB: A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327: 1272-1278, 1992.
21. Vousden K: Interactions of human papillomavirus trasforming proteins with the products of tumor suppressor genes. FASEB J 7: 872-879, 1993.
22. Yokota J, Tsukada Y, Nakajiama T, Gotoh M, Shimosato Y, Mori N, Tsunokawa Y, Sugimura T, Tereda M: Loss of heterozygosity on the short arm of chromosome 3 in carcinoma of the uterine cervix. Cancer Res 49: 3598-3601, 1989.
23. Srivatsan ES, Brijesh CM, Venugopalan M, Wilczynski SP: Loss of heterozygosity for alleles on chromosome 11 in cervical carcinoma. Am J Hum Genet 49: 868-877, 1991.
24. Riou GF, Bourhis J, Monique GL: The c-myc proto-oncogene in invasive carcinomas of the uterine cervix: clinical relevance of overexpression in early stages of the cancer. Anticancer Res 10: 1225-1232, 1990
25. Riou GF, Barrois M, Zong-Mei S, Duvillard P, Lhomme C: Somatic deletions and mutations of c-Ha-ras gene in human cervical cancer. Oncogene 3: 329-333, 1988.
26. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, De Nictolis M, Romanini C, Biagini G: Modulation of expression of p53 and cell proliferation in locally advanced cervical carcinoma after neoadjuvant combination chemotherapy. Eur J Obstet Gynaecol Reprod Biol 63: 31-36, 1995.